Latest Price Forecast of Crizotinib/Xalkori in 2025: Will treatment costs decrease in the future?

Crizotinib , marketed in China under its trade name XALKORI, is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC) patients with specific genetic mutations. Its main indications include patients with non-small cell lung cancer who are refractory to epidermal growth factor receptor (EGFR) inhibitors treatment, and patients with anaplastic lymphoma kinase (ALK) rearrangements or ROS1 rearrangements. Crizotinib blocks the growth and spread of tumor cells by inhibiting these abnormal signaling pathways. Clinical studies have shown that crizotinib plays a significant role in improving patient survival rates and quality of life.

As for price, crizotinib is available on the market in packaging options of 250mg*60 pills and 200mg*60 pills. The market price is often more than RMB 10,000 per box. For patients who meet the treatment conditions, the national medical insurance policy can reimburse part of the expenses, so the financial burden on the patients is relatively light. However, even with the support of medical insurance, patients still need to bear certain out-of-pocket expenses, which is still a big challenge for some patients with limited financial conditions.

In addition to the original drug, generic drugs of crizotinib have appeared in overseas markets. These generic drugs are basically the same in ingredients as the original drug and are more economical in price. For example, the price of generic crizotinib produced in Bangladesh and Laos in the format of 250mg*60 tablets may only be more than 1,000 yuan (the specific price may fluctuate due to exchange rates). Although generic drugs have price advantages, patients still need to pay attention to the legality and quality assurance of the drugs when choosing.

Going forward, it's unclear whether treatment costs will decrease. On the one hand, with the continuous advancement of medical technology, the development of new treatment options and drugs may gradually replace existing drugs, leading to intensified market competition and expected to reduce treatment costs. On the other hand, the R&D and production costs of drugs are still high, especially for targeted drugs targeting specific targets, and price reductions may not be realized quickly. In addition, changes in medical insurance policies and the inclusion of drugs in the medical insurance catalog will also affect the trend of treatment costs.

Reference materials:https://go.drugbank.com/drugs/DB08865